Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19922959 | 1.00 | ENPP1 (0.33) | ENPP1CCNE2CCNE1CDK2TGFBR1 | |
| SCHEMBL19922970 | 0.90 | NTRK1 (0.30) | — | |
| SCHEMBL19922833 | 0.89 | ABCB1 (0.32) | — | |
| SCHEMBL19922962 | 0.85 | MPO (0.31) | MPO | |
| SCHEMBL19922676 | 0.85 | ENPP1 (0.33) | ENPP1TGFBR1MAPK14HCAR2HTR2C | |
| SCHEMBL30450190 | 0.83 | EPHB4 (0.35) | CCNE2CCNE1CDK2HCAR2KDM6B | |
| SCHEMBL19922742 | 0.83 | EPHB4 (0.35) | CCNE2CCNE1CDK2HCAR2KDM6B | |
| SCHEMBL19922992 | 0.83 | TGFBR1 (0.31) | TGFBR1MAPK14MPOADORA2AADORA1 | |
| SCHEMBL19922778 | 0.82 | AR (0.34) | — | |
| SCHEMBL19934120 | 0.76 | KDM4E (0.36) | HCAR2HTR2CHTR2BKDM6BABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326761-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| CN-117105939-A | Fused bicyclic sGC stimulators | 帝善多制药公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-109790167-B | SGC stimulators | 塞科里昂医疗股份有限公司 | 2023-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326761-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | ENPP1 400/4885CCNE2 4103/4885CCNE1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.